贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子的影响

发布时间：2018-06-17 17:53

  本文选题：贝伐单抗 + 顺铂　； 参考：《中国临床药理学杂志》2017年23期

【摘要】：目的探讨贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子(VEGF)的影响。方法对SBF级健康BALB/c裸鼠右腋下注射处于对数生长期鼠源性Lewis肺癌细胞,建立肺癌小鼠模型。将造模成功的小鼠随机分为模型组、实验A组、实验B组和实验C组,每组8只;另取8只健康裸鼠作为对照组。模型组和对照组均给予腹腔注射0.9%Na Cl 0.4 m L,每周2次;实验A组给予腹腔注射15 mg·kg~(-1)贝伐单抗,每周2次;实验B组给予腹腔注射5 mg·kg~(-1)顺铂,每周2次;实验C组给予腹腔注射15 mg·kg~(-1)贝伐单抗和5 mg·kg~(-1)顺铂,每周2次。5组裸鼠均连续给药2周后处死,摘眼球取血和取瘤称重。比较5组裸鼠的抵瘤率、免疫功能、VEGF水平。结果治疗后,实验A,B,C组的抑瘤率分别为(46.57±5.45)%,(72.03±8.24)%和(87.47±9.02)%,任意2组比较,差异均有统计学意义(均P0.05)。治疗后,对照组、模型组和实验A,B,C组的白细胞介素-2水平分别为(37.12±5.24),(15.24±2.36),(26.45±4.45),(7.36±1.02)和(22.32±3.25)pg·m L-1,白细胞介素-6水平分别为(125.36±15.24),(54.32±6.32),(86.45±10.12),(24.36±3.45)和(74.36±8.54)pg·m L-1,肿瘤坏死因子-α水平分别为(80.12±4.25),(32.45±4.56),(62.54±7.24),(17.36±2.54)和(52.12±6.35)pg·m L-1,CD3+分别为(66.45±6.74)%,(38.52±4.56)%,(50.32±5.23)%,(21.32±3.24)%和(44.12±4.65)%,CD4+分别为(42.36±5.12)%,(26.02±3.54)%,(34.12±4.21)%,(20.42±3.25)%和(30.25±3.45)%,CD4+/CD8+比率分别为(1.83±0.32),(0.83±0.14),(1.36±0.30),(0.54±0.10)和(1.06±0.22),血清中VEGF分别为(10.42±1.24),(33.45±4.32),(23.36±2.45),(28.12±3.25)和(20.12±2.32)pg·m L-1,肿瘤组织中VEGF分别为(0.21±0.06),(1.04±0.21),(0.51±0.10),(0.76±0.12)和(0.38±0.05)pg·m L-1,实验A,B,C组的上述指标与模型组比较,差异均有统计学意义(均P0.05);实验B,C组的上述指标与实验A组比较,差异均有统计学意义(均P0.05);实验B组的上述指标和实验C组比较,差异均有统计学意义(均P0.05)。结论贝伐单抗联合顺铂有助于抑制Lewis肺癌荷瘤小鼠瘤体生长,可能与其能够改善免疫功能、降低血管内皮生长因子含量等因素有关。
[Abstract]:Objective to investigate the effect of bevacizumab combined with cisplatin on immune function and vascular endothelial growth factor (VEGF) in Lewis lung cancer bearing mice. Methods the right subaxillary injection of murine Lewis lung cancer cells at logarithmic growth stage in SBF grade BALB / c nude mice was used to establish lung cancer model in mice. The mice were randomly divided into three groups: model group, experimental group A, experimental group B and experimental group C with 8 mice in each group, and 8 healthy nude mice as control group. The model group and control group were given intraperitoneal injection of 0.9% NaCl 0.4 mL twice a week, group A received intraperitoneal injection of 15 mg 路kg ~ (-1) bevacizumab twice a week, group B received intraperitoneal injection of 5 mg 路kg ~ (-1) cisplatin twice a week. Group C was given intraperitoneal injection of 15 mg 路kg ~ (-1) bevacizumab and 5 mg 路kg ~ (-1) 路kg ~ (-1) of cisplatin. The nude mice in group 5 were sacrificed after 2 weeks of continuous administration, and blood and tumor were removed and weighed. The tumor arrival rate and the level of VEGF in immune function were compared in 5 groups of nude mice. Results after treatment, the tumor inhibition rates of the experimental group A (46.57 卤5.45) were 72.03 卤8.24% and 87.47 卤9.02%, respectively. The difference between any two groups was statistically significant (all P 0.05). After treatment, the control group, 妯″瀷缁勫拰瀹為獙A,B,C缁勭殑鐧界粏鑳炰粙绱，

本文编号：2031934